

Thymic Hyperplasia-Associated Myasthenia Gravis in the Setting of Coexisting Graves' Disease

Yotsapon Thewjitcharoen, Veekij Veerasomboonin, Thep Himathongkam

Theptarin Diabetes, Thyroid, and Endocrine Center, ViMUT-Theptarin Hospital, Bangkok, Thailand

Key words: thymic hyperplasia, myasthenia gravis, Graves' disease

Thymic hyperplasia secondary to Graves' disease (GD) is a well-recognized entity.¹ Still, other causes of thymic hyperplasia in the presence of euthyroidism, especially the occurrence of massive thymic hyperplasia, should be investigated.² The clinical features of myasthenia gravis (MG) and thyroid eye disease (TED) may be similar, while thymic hyperplasia may occur in both conditions. Herein, we report an interesting case of the coexistence of severe TED and MG.

A 40-year-old Thai female diagnosed with severe TED requiring orbital decompression and intravenous methylprednisolone presented with left eye ptosis and chewing weakness for one month. Physical examination showed bilateral proptosis (19 mm in right eye, 21 mm in left eye) with eyelid retraction, erythema and edema of the eyelids and left eye ptosis. She denied limb muscle weakness, hoarse voice, or difficulty breathing. Her previous history included hypothyroidism after thyroidectomy for GD 18




Figure 1. (A) Computed tomography images demonstrated a 10 × 9 × 1.6 cm thymic enlargement (thymic hyperplasia outline as shown in Figure 1A). (B) Chest X-ray at the time of thyroidectomy revealed no widening mediastinum (the brightness of the image is adjusted to enhance visibility). (C) Clinical course of severe thyroid eye disease from the initial presentation (18 months prior to the diagnosis of myasthenia gravis) which demonstrated inflamed bulging of both eyes and strabismus at left eye, new-onset left eye ptosis at the time of myasthenia gravis diagnosis, and after multiple surgical procedures including decompression surgery followed by strabismus surgeries.

months earlier. At the initial diagnosis of GD, laboratory tests were notable for highly elevated serum thyrotropin receptor antibody (TRAb) at 14.5 U/L (normal range <1.75 U/L). Anti-acetylcholine receptor antibody was positive, confirming the diagnosis of MG. A chest computed tomography scan showed a 10 × 9 × 1.6 cm thymic enlargement with a well-demarcated margin and mild homogeneous enhancement. The patient was euthyroid at the time, on LT4 replacement for surgical hypothyroidism. Serum TRAb was decreased at 1.39 U/L. There was no mediastinal widening on the previous chest X-ray (CXR) at the time of thyroidectomy. The patient underwent video-assisted thoracoscopic thymectomy. The pathologic results revealed non-neoplastic thymic tissue with focal thymic epithelial hyperplasia. One year after thymectomy, her symptoms had significantly improved and she was prescribed oral azathioprine 50 mg/day without prednisolone. Once her TED became inactive, strabismus and eyelid surgeries were performed.

Our case highlights a diagnostic dilemma in the background of coexisting GD and MG. Thymic hyperplasia could be secondary to both GD and MG.³ However, the previous CXR and clinical course of hyperthyroidism in this patient were essential to differentiate between both conditions. This present case emphasized that clues from all relevant imaging must be obtained to accurately determine the etiology of thymic hyperplasia in cases of coexistent GD and MG.

Ethical Consideration

Patient consent was obtained before submission of the manuscript.

Statement of Authorship

All authors certified fulfilment of ICMJE authorship criteria.

CRedit Author Statement

YT: Conceptualization, Methodology, Investigation, Writing – original draft preparation, Project administration; **VV:** Resources, Data Curation, Writing - review and editing, Visualization; **TH:** Writing – review and editing, Supervision, Funding acquisition.

Data Availability Statement

Datasets generated and analyzed are included in the published article.

Author Disclosure

None.

Funding Source

None.

References

1. Popoveniuc G, Sharma M, Devdhar M, et al. Graves' disease and thymic hyperplasia: The relationship of thymic volume to thyroid function. *Thyroid*. 2010;20:1015-8. PMID: 20718680 DOI: 10.1089/thy.2009.0383
2. Haider U, Richards P, Gianoukakis AG. Thymic hyperplasia associated with Graves' disease: Pathophysiology and proposed management algorithm. *Thyroid*. 2017;27(8): 994-1000. PMID: 28578595 DOI: 10.1089/thy.2017.0086
3. Lopomo A, Berrih-Aknin S. Autoimmune thyroiditis and myasthenia gravis. *Front Endocrinol (Lausanne)*. 2017;8:169. PMID: 28751878 PMID: PMC5508005 DOI: 10.3389/fendo.2017.00169

Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of: (1) Authorship Certification, that authors contributed substantially to the work, that the manuscript has been read and approved by all authors, and that the requirements for authorship have been met by each author; (2) the Author Declaration, that the article represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere, that the article does not infringe or violate any copyrights or intellectual property rights; that no references have been made to predatory/suspected predatory journals; and that use of artificial intelligence (AI) or AI-assisted technologies shall be declared to include the name of the AI tool or service used; (3) the Author Contribution Disclosure, which lists the specific contributions of authors; (4) the Author Publishing Agreement which retains author copyright, grants publishing and distribution rights to JAFES, and allows JAFES to apply and enforce an Attribution-Non-Commercial Creative Commons user license; and (5) the Conversion to Visual Abstracts (*optional for original articles only) to improve dissemination to practitioners and lay readers. Authors are also required to accomplish, sign, and submit the signed ICMJE form for Disclosure of Potential Conflicts of Interest. For original articles, authors are required to submit a scanned copy of the Ethics Review Approval of their research as well as registration in trial registries as appropriate. For manuscripts reporting data from studies involving animals, authors are required to submit a scanned copy of the Institutional Animal Care and Use Committee approval. For Case Reports or Series, and Images in Endocrinology, consent forms, are required for the publication of information about patients; otherwise, appropriate ethical clearance has been obtained from the institutional review board. Articles and any other material published in the JAFES represent the work of the author(s) and should not be construed to reflect the opinions of the Editors or the Publisher.



Had an intriguing discussion in Grand Rounds?
Share your Clinical Case Seminars at
JAFES@Asia.com.